Description
Anti-CD248 antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
Applications
"On-target" tumor antigen binding
Technology
ATP-mediated antibody engineering technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD248 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD248 Molecule
Background
Ontuxizumab; 946415-62-9; MORAb-004; CD248; CD248 molecule; endosialin; CD164 sialomucin like 1; CD164L1; CD248 antigen; endosialin; endosialin; TEM1; tumor endothelial marker 1; 2610111G01Rik; CD164 sialomucin-like 1; CD248 antigen; endosialin; CD164L1; MGC119478;
Antibody Clone
AES-0622-ZP844
Description
Anti-CD248 antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
